From @jama.com: In resected non-small cell lung #cancer, adjuvant #nivolumab following standard care was not associated with improved survival or recurrence risk compared with observation, even in tumors with high PD-L1 expression.
#ASCO26 @ascocancer.bsky.social
ja.ma/3RypEQ2
